Bio Farma and Novo Nordisk Indonesia have entered into a collaboration to develop local manufacturing processes for diabetes medications in Indonesia. This partnership aims to improve access to affordable and high-quality diabetes treatments, enhance chronic disease management, and strengthen Indonesia’s healthcare system.
Bio Farma President Director Shadiq Akasya emphasized the importance of government support in achieving the goals of this collaboration. Sreerekha Sreenivasan, Vice President and General Manager of Novo Nordisk Indonesia, highlighted that the partnership builds on an existing intergovernmental agreement between Indonesia and Denmark.
Novo Nordisk has been actively involved in diabetes care in Indonesia, including training programs for healthcare workers in collaboration with the Ministry of Health, the Indonesian Society of Endocrinology (Perkeni), and other partners. These initiatives focus on capacity building, patient education, and health evaluation in 176 hospitals across Indonesia.
With an estimated 19.5 million people currently living with diabetes in Indonesia and the number projected to rise to 28.6 million by 2045, this collaboration is seen as a critical step toward addressing one of the nation’s leading causes of death.
(Source: Tempo)
